Delivery Order SPE2DB24D8002-SPE2DB24FJMVF
Award Date
8/27/24
Potential Completion Date
8/28/24
Potential Value
$5.4K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, identified as SPE2DB24D8002|SPE2DB25FJNKP, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of Dupixent 300 mg/2 ml syringes, with a ceiling value of $9,629.49 and a period of performance extending through March 31, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. Department of Defense,...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, involves the delivery of Dupixent 300 mg/2 ml syringes to the Defense Logistics Agency (DLA) Troop Support Medical division. The contract has a firm fixed price of $2,345.09 and a period of performance through November 15, 2023. This award is part of Dakota Drug's larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00, which allows the company...
The U.S. government's Defense Logistics Agency (DLA) awarded a $26,588.72 firm-fixed-price delivery order contract (SPE2DX15D8003|SPE2DX24F7D7B) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of Dupixent 300 mg/2 ml syringes. The contract has a performance period through May 8, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery Contract (SPE2DB24D8001) as part of the DLA's ECAT...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract has a firm fixed price of $3,179.33 and a period of performance through February 26, 2025. Dakota Drug, Inc. holds a significant Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999.00, under the DLA Troop Support Medical's ECAT Generation V Program. This IDC allows...
The federal contract award with ID SPE2DB24D8003|SPE2DB25FJUCD was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $1,867.25 firm-fixed-price delivery order is for the supply of the pharmaceutical product Dupixent 300 mg/2 ml syringe. This award is associated with Dakota Drug, Inc.'s larger Indefinite Delivery Contract (IDC) SPE2DB24D8001 valued at $999,999,999.00, which is part of the DLA Troop Support Medical's ECAT...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the supply of the pharmaceutical product Dupixent 300 mg/2 ml syringe. The contract has a ceiling value of $7,469.04 and a period of performance ending on September 17, 2024. Dakota Drug, Inc. is a prime contractor to the DLA Troop Support Medical, playing a crucial role in supporting the medical supply chain operations for...
This is a federal contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Dupixent 300 mg/2 ml syringes. The contract, identified as SPE2DX15D8003|SPE2DX24F7C1H, has a ceiling value of $23,631.00 and a completion date of December 27, 2023. The contract is a Delivery Order with a Firm Fixed Price pricing type. Dakota Drug, Inc. is a key supplier for the DLA Troop Support Medical division, providing a wide...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $6,356.82. The contract is a delivery order with a firm fixed price and an ultimate completion date of March 12, 2025. The contract is for the delivery of Dupixent 300 mg/2 ml syringes to support U.S. Armed Forces medical operations. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $7,091.73 to Dakota Drug, Inc., a self-certified small disadvantaged business located in Anoka, Minnesota. This contract, with a performance period ending on March 4, 2024, is for the delivery of Dupixent 300 mg/2 ml syringes. This award is part of a larger Indefinite Delivery Contract (IDC), identified as SPE2DB24D8001, which allows Dakota Drug, Inc. to provide a wide range of pharmaceutical...
This federal contract award, valued at $8,116.86, was issued by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business operating as a for-profit subchapter S corporation. The contract is a firm fixed-price delivery order for the provision of the pharmaceutical product Dupixent 300 mg/2 ml syringe, 2 ml. This award is associated with a larger Indefinite Delivery Contract (IDC) between Dakota Drug, Inc. and the DLA Troop Support Medical, valued at...